| Pharmaceutical quality by design: product and process development, understanding, and control LX Yu Pharmaceutical research 25 (4), 781-791, 2008 | 1551 | 2008 |
| Understanding pharmaceutical quality by design LX Yu, G Amidon, MA Khan, SW Hoag, J Polli, GK Raju, J Woodcock The AAPS journal 16 (4), 771-783, 2014 | 1216 | 2014 |
| Biopharmaceutics classification system: the scientific basis for biowaiver extensions LX Yu, GL Amidon, JE Polli, H Zhao, MU Mehta, DP Conner, VP Shah, ... Pharmaceutical research 19 (7), 921-925, 2002 | 911* | 2002 |
| Modernizing pharmaceutical manufacturing: from batch to continuous production SL Lee, TF O’Connor, X Yang, CN Cruz, S Chatterjee, RD Madurawe, ... Journal of Pharmaceutical Innovation 10, 191-199, 2015 | 867 | 2015 |
| A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan T Takagi, C Ramachandran, M Bermejo, S Yamashita, LX Yu, GL Amidon Molecular pharmaceutics 3 (6), 631-643, 2006 | 762 | 2006 |
| Developing solid oral dosage forms: pharmaceutical theory and practice Y Qiu, Y Chen, GGZ Zhang, L Yu, RV Mantri Academic press, 2016 | 571 | 2016 |
| A compartmental absorption and transit model for estimating oral drug absorption LX Yu, GL Amidon International journal of pharmaceutics 186 (2), 119-125, 1999 | 525 | 1999 |
| Quality by design: concepts for ANDAs RA Lionberger, SL Lee, LM Lee, A Raw, LX Yu The AAPS journal 10 (2), 268-276, 2008 | 480 | 2008 |
| Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model X Cao, ST Gibbs, L Fang, HA Miller, CP Landowski, HC Shin, ... Pharmaceutical research 23, 1675-1686, 2006 | 445 | 2006 |
| Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption LX Yu, E Lipka, JR Crison, GL Amidon Advanced drug delivery reviews 19 (3), 359-376, 1996 | 443 | 1996 |
| Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration BM Davit, PE Nwakama, GJ Buehler, DP Conner, SH Haidar, DT Patel, ... Annals of Pharmacotherapy 43 (10), 1583-1597, 2009 | 425 | 2009 |
| Applications of process analytical technology to crystallization processes LX Yu, RA Lionberger, AS Raw, R D'Costa, H Wu, AS Hussain Advanced Drug Delivery Reviews 56 (3), 349-369, 2004 | 410 | 2004 |
| Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products RK Chang, A Raw, R Lionberger, L Yu The AAPS journal 15, 41-52, 2013 | 372 | 2013 |
| Dissolution testing for generic drugs: an FDA perspective OM Anand, LX Yu, DP Conner, BM Davit The AAPS journal 13, 328-335, 2011 | 339 | 2011 |
| Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability1 L Yu, A Bridgers, J Polli, A Vickers, S Long, A Roy, R Winnike, M Coffin Pharmaceutical research 16, 1812-1817, 1999 | 293 | 1999 |
| Compartmental transit and dispersion model analysis of small intestinal transit flow in humans LX Yu, JR Crison, GL Amidon International journal of pharmaceutics 140 (1), 111-118, 1996 | 280 | 1996 |
| Bioequivalence approaches for highly variable drugs and drug products SH Haidar, B Davit, ML Chen, D Conner, LM Lee, QH Li, R Lionberger, ... Pharmaceutical research 25, 237-241, 2008 | 252 | 2008 |
| Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs) AS Raw, MS Furness, DS Gill, RC Adams, FO Holcombe, LX Yu Advanced drug delivery reviews 56 (3), 397-414, 2004 | 246 | 2004 |
| Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs XY Lawrence, AS Carlin, GL Amidon, AS Hussain International journal of pharmaceutics 270 (1-2), 221-227, 2004 | 235 | 2004 |
| Effect of common excipients on Caco-2 transport of low-permeability drugs BD Rege, XY Lawrence, AS Hussain, JE Polli Journal of pharmaceutical sciences 90 (11), 1776-1786, 2001 | 235 | 2001 |
Robert LionbergerOffice of Generic Drugs, Food and Drug AdministrationVerified email at fda.hhs.gov
